Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
P levels were different across smoking categories in both sexes and cohorts (ANOVA p < 0.001); this difference was due to higher P in current smokers (Tukey’s tests > 0.05 between former and never smokers).General characteristics of subjects in RS-I and RS-II with serum phosphate levels, BMI and smoking information available, stratified by sexMenWomenMean (SD)MinimumMaximumMean (SD)MinimumMaximum(n: 1577)(n: 2154)(I) RS-IAge (year)71.8 (6.53)61.496.772.5 (7.06)61.4100.9BMI (kg/m2)26.3 (3.18)17.641.127.3 (4.37)15.247.9Calcium (mg/dL)9.65 (0.39)6.2611.69.79 (0.41)6.9812.9Phosphate (mg/dL)3.15 (0.44)1.917.623.62 (0.43)2.285.2525(OH)D (nmol/L)61.4 (25.5)8.99173.847.9 (22.5)5.14134.4CRP (mg/L)4.24 (7.22)0.20115.03.93 (6.66)0.20145.0Glucose (mmol/L)6.06 (1.62)4.1020.55.87 (1.46)1.6019.5Creatinine (μmol/L)92.4 (33.6)43.01107.072.1 (14.8)34.0263.0eGFR (mL/min)73.8 (14.4)3.55108.873.8 (13.9)14.9113.7Mg (mmol/L)0.85 (0.06)0.601.130.85 (0.06)0.581.17Chol to HDL ratio4.69 (1.32)1.5210.24.30 (1.30)1.1914.1Men (n: 1133)Women (n: 1361)(II) RS-IIAge (year)64.3 (7.48)55.193.964.9 (8.17)55.195.3BMI (kg/m2)26.9 (3.36)16.840.527.4 (4.46)15.950.5Calcium (mg/dL)9.57 (0.34)8.5811.89.68 (0.34)8.7011.3Phosphate (mg/dL)3.09 (0.44)1.394.663.54 (0.44)1.825.1225(OH)D (nmol/L)65.7 (27.9)0.25175.058.9 (27.5)5.84162.5CRP (mg/L)2.37 (4.60)0.3051.82.33 (4.16)0.0065.5Glucose (mmol/L)6.17 (1.78)3.9022.15.87 (1.47)3.8025.9Creatinine (μmol/L)87.8 (18.7)53.0349.069.2 (11.8)40.0165.0eGFR (mL/min)80.9 (13.9)14.0111.680.6 (13.7)26.8108.4Mg (mmol/L)0.83 (0.06)0.341.020.83 (0.06)0.431.06Chol to HDL ratio4.77 (1.34)1.8312.44.23 (1.22)1.5211.1BMI body mass index, 25(OH)D 25-hydroxyvitamin D levels, CRP C-reactive protein, eGFR estimated glomerular filtration rate, Mg magnesium, Chol to HDL ratio total cholesterol to HDL cholesterol ratioConversion to SI Units: to convert 25-hydroxyvitamin D levels to ng/mL multiply by 0.4; to convert glucose to mg/dL multiply by 18.02; to convert creatinine to mg/dL multiply by 0.011; to convert magnesium to mg/dL multiply by 2.43 General characteristics of subjects in RS-I and RS-II according to quintiles of fasting phosphate levelsMenWomenPhosphate in quintilesPhosphate in quintiles12345 p* 12345 p* (I) RS-I N (mg/dL)315 (2.56)315 (2.92)316 (3.15)315 (3.37)316 (3.77)431 (3.02)431 (3.40)431 (3.62)431 (3.83)430 (4.21) Age (year)71.672.471.471.971.80.96873.072.372.872.471.9 0.049 BMI (kg/m2)26.726.426.226.226.0 0.005 29.027.527.226.725.9 < 0.001 Ever smoke (%)90%87%92%92%95% 0.008 47%47%50%53%51%0.091 Calcium (mg/dL)9.599.669.629.669.72 < 0.001 9.779.809.769.799.84 0.026 25 (OH) D (nmol/L)62.862.662.759.159.9 0.034 45.448.946.848.650.1 0.035 CRP (mg/L)4.573.624.153.795.120.3404.924.063.793.603.23 < 0.001 Glucose (mmol/L)6.095.966.046.046.150.5296.185.795.875.775.77 < 0.001 Prevalent DM (%)14%12%13%14%15%0.42417%10%12%9%9% 0.001 Creatinine (μmol/L)91.492.790.291.396.20.16772.472.771.571.971.90.652 eGFR (mL/min)73.972.075.074.273.70.43273.173.174.274.174.40.356 Mg (mmol/L)0.840.840.850.850.86 0.002 0.840.850.850.850.86 < 0.001 Chol to HDL ratio4.754.934.754.564.47 < 0.001 4.414.424.334.174.18 < 0.001 Prevalent CVD (%)7%9%8%7%10%0.2214%2%2%4%3%0.712(II) RS-II N (mg/dL)226 (2.49)227 (2.86)226 (3.07)227 (3.31)227 (3.71)272 (2.92)272 (3.32)272 (3.54)272 (3.77)273 (4.14) Age (year)63.864.465.064.763.80.88465.466.264.465.263.1 < 0.001 BMI (kg/m2)27.126.726.826.727.30.48229.127.927.426.826.0 < 0.001 Ever smoke (%)86%81%80%87%89%0.14257%62%57%58%63%0.642 Calcium (mg/dL)9.509.599.539.589.64 < 0.001 9.649.669.709.689.75 0.001 25 (OH) D (nmol/L)66.668.065.165.762.80.10357.157.258.358.963.20.071 CRP (mg/L)2.412.222.421.882.930.4792.822.541.922.342.01 0.037 Glucose (mmol/L)6.085.986.246.066.50 0.013 6.105.845.795.785.84 0.049 Prevalent DM (%)11%9%15%11%21% 0.002 12%9%10%9%7%0.164 Creatinine (μmol/L)87.687.488.786.888.20.91569.570.068.469.268.90.923 eGFR (mL/min)80.981.379.281.381.70.47579.779.181.680.581.80.691 Mg (mmol/L)0.830.830.830.830.840.2900.820.830.830.830.84 < 0.001 Chol to HDL ratio4.934.714.624.664.930.9064.354.204.314.154.12 0.042 Prevalent CVD (%)8%11%13%9%13%0.3513%3%3%3%1%0.608Statistically significant p-values (<0.05) are highlighted in bold font*P values corresponds to age-adjusted significance of trend across quintilesBMI body mass index, 25(OH)D 25-hydroxyvitamin D levels, CRP C-reactive protein, prevalent DM prevalent diabetes mellitus, eGFR estimated glomerular filtration rate, Mg magnesium, Chol to HDL ratio total cholesterol to HDL cholesterol ratio, prevalent CVD prevalent cardiovascular diseaseConversion to SI Units: to convert 25-hydroxyvitamin D levels to ng/mL multiply by 0.4; to convert glucose to mg/dL multiply by 18.02; to convert creatinine to mg/dL multiply by 0.011; to convert magnesium to mg/dL multiply by 2.43
Source: Serum phosphate correlates. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All participants were 55 years or more at recruitment and have been assessed at baseline and through several follow-up visits.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men
Study design awaiting verification · European Journal of Epidemiology · 2018
Original publication title
Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men
© The Author(s) 2018
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: Electronic supplementary material
The online version of this article (10.1007/s10654-018-0407-7) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAuthors’ abstract
Hyperphosphatemia has been associated with increased mortality in chronic kidney disease but the nature of such a relation in the general population is unclear. To investigate the association between phosphate (P) levels and all-cause and cause-specific mortality, we assessed two cohorts from the Rotterdam Study, with follow-up of 14.5 (RS-I) and 10.9 (RS-II) years until January 2012 with availability of fasting phosphate levels. Deaths were classified according to International Classification of Diseases into 7 groups: cardiovascular, cancer, infections, external, dementia, chronic lung diseases and other causes.
Sex-stratified Weibull and competing-risks models were adjusted for age, BMI and smoking. Hazard ratios are expressed per 1 mg/dL increase in phosphate levels. The total number of participants included 3731 (RS-I, 2154 women) and 2494 (RS-II, 1361 women) subjects. The main outcome measures were all-cause and cause-specific mortality. A significant positive association was found between phosphate and all-cause mortality in men (pooled HR (95% CI): 1.46 (1.26 to 1.69)) but not in women (0.90 (0.77 to 1.05)). In men, higher phosphate increased the risk for cardiovascular mortality (1.66 (1.29 to 2.14)), other causes (1.67 (1.16 to 2.40)) and chronic lung disease mortality (1.94 (1.02 to 3.72)), the latter driven by mortality due to chronic obstructive pulmonary disease (COPD) (4.44 (2.08 to 9.49)).
No relations were found for mortality due to infections, cancer, dementia or external causes. In conclusion, serum P is associated with increased all-cause, cardiovascular and COPD mortality in men but not women. The association with COPD mortality is novel and needs further research on underlying mechanisms.
Electronic supplementary material
The online version of this article (10.1007/s10654-018-0407-7) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men
Natalia Campos-Obando; Lies Lahousse; Guy Brusselle; Bruno H. Stricker; Albert Hofman; Oscar H. Franco; André G. Uitterlinden; M. Carola Zillikens
European Journal of Epidemiology · 2018
© The Author(s) 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.http://dx.doi.org/10.13039/501100003061Erasmus Medisch Centrumhttp://dx.doi.org/10.13039/501100001828Erasmus Universiteit Rotterdamhttp://dx.doi.org/10.13039/501100001826ZonMwResearch Institute for Diseases in the Elderly RIDEhttp://dx.doi.org/10.13039/501100003245Ministerie van Onderwijs, Cultuur en WetenschapMinistry for Health, Welfare and SportsEuropean Commission (DG XII)Municipality of RotterdamRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:10:02.348586+00:00
DOI: 10.1007/s10654-018-0407-7 · PMC6133003